

## References

### I-9

1. Zimran A, Gonzalez-Rodriguez D, Abrahamov A, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. *Blood Cells Mol Dis.* 2015;54(1):9-16.
2. Abbas R, Park G, Damle B, et al. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher *PLoS One.* 2015;8;10(6).
3. Hughes D, Gonzalez D, Lukina A, et Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials. *Am J Hematol.* 2015;90(7):584-91.
4. Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, et Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase. *Blood Cells Mol Dis.* 2016.
5. Serratrice C, Carballo S, Serratrice J and Stirnemann Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. *Core Evid.* 2016;11:37-4.
6. Elstein D, Burrow TA, Charrow J, et al. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher *Mol Genet Metab.*2016;1-5.
7. Elstein D, Abrahamov A, Oz A, et 13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease. *Bld Cell Mol Dis.* 2015;415- 418.
8. Polinski JM, Kowal MK, Gagnon M, et Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016. Accessed November 9, 2017.
9. ASHP Guidelines on Home Infusion Pharmacy Services, Accessed September 2, 2017.
10. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
11. MICROMEDEX®SOLUTIONS 2020. Imiglucerase.
12. MICROMEDEX®SOLUTIONS 2020. Velaglucerase Alfa.
13. Micromedex®Solutions Compendia. 2020. Taliglucerase alfa.
14. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Imiglucerase. 2020.
15. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Taliglucerase Alfa. 2020.

16. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Velaglucerase Alfa. 2020.
17. Stirnemann J, Belmatoug N, Camou F, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. *International Journal of Molecular Sciences*. 2017;18(2):441.
18. Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. *Expert Rev Endocrinol Metab*. 2018;13(2):107-
19. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. *Molecular Genetics and Metabolism*. 2017;120(1-2);47-56.
20. Pastores GM, Hughes DA. Gaucher disease. GeneReviews. 2018;1-35.
21. Cerezyme (imiglucerase) for injection [package insert]. Genzyme Corporation. Cambridge, MA. Revised 04/2018
22. Elelyso (taliglucerase alfa) for injection, for intravenous use [package insert]. Pfizer Labs. New York, New York. Revised 10/2019.
23. VPRIV (velaglucerase alfa) for injection, for intravenous use [package insert]. Shire Human Genetic Therapies, Inc. Lexington, MA. Revised 11/2019.
24. National Institute of Health. National Organization for Rare Disorders. Gaucher Disease. Last published: 2018.